Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

The COVID-19 International Modelling Consortium (CoMo Consortium)

COVID-19 is continuing to spread across the world at a rapid rate. By 30 April 2020, the pandemic had affected at least 185 countries/regions, with more than 4 million confirmed cases and in excess of 200,000 deaths globally. The pandemic has presented a myriad of challenges for health care systems around the world, including pressures on health care staff, general hospital beds, intensive care capacity and specialized equipment. In addition to the health effects of the disease, lockdown measures to contain the disease have placed a significant economic burden on countries and communities. Policymakers must balance curtailing the negative health effects of the pandemic against minimizing the economic impact on societies, calibrating these decisions for the epidemiological, social, cultural and infrastructure context of an individual country. There is currently no treatment or vaccine for COVID-19, so countries that choose to try to interrupt its spread must rely on non-pharmaceutical interventions (NPIs); these NPIs fall into various categories of behaviour change, including self-isolation for symptomatic individuals, increased hand hygiene, and physical distancing in social settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford together with academic colleagues at Cornell University and is partnering with infectious disease modellers and other public health experts from more than 40 countries across Africa, Asia, and South and North America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

The CoMo Consortium has developed an age-structured, compartmental SEIR (susceptible-exposed-infectious-recovered) model to estimate the trajectory of COVID-19 based on different scenarios and to assess the potential impact of the various NPIs, as well as treatments and vaccines, when they become available. A user-friendly, web-based interface enables training on and use of the model by member modelling groups, while dashboards and visualization tools allow policymakers to see the predicted impacts of different NPIs in real time. The CoMo Consortium comprises several working groups, with each group playing a specific role, as outlined below.

CoMo Consortium working groups

  • Policy support. Facilitating a direct link between the modellers (from multiple countries) involved in developing the models and interpreting their outputs, the in-country experts and the policymakers in each country.
  • Model development. Writing, coding, debugging and updating the primary model structure.
  • Interface development. Creating a web-based interface that enables non-modellers to run the models, based on their local parameters.
  • Economic modelling. Conducting modelling to assess the economic costs and impacts arising from an intervention or a suite of interventions.
  • Evidence synthesis. Combining scientific evidence relating to the COVID-19 pandemic with model projections, economics and financing to create evidence-based policy briefs.
  • Outreach and communications. Engaging both in-country experts and policymakers who are seeking additional modelling support to deal with their specific COVID-19 situation.

CoMo Consortium model outputs

A diagram of the baseline model structure, including both age-structured epidemiological and health care utilization components

A diagram of the baseline model structure, including both age-structured epidemiological and health care utilization components

The predictions of the model can enable policymakers to make data-based decisions to inform their public health responses, such as:

  • The impact of the various mitigation strategies on virus transmission, mechanisms for ‘flattening he epidemic curve’, lockdown release strategies, and deciding which interventions will be most effective in their specific context.
  • The comparative demand for general hospital beds and ICU beds under different intervention strategies.
  • The quantity of tests, personal protective equipment, ventilators and other supportive tools needed for the diagnosis and treatment of patients with COVID-19, and the costs of the equipment needed.

Graphics

 

Examples of graphs showing the predicted effects of different combinations of non-pharmaceutical interventions

The CoMo Consortium model is currently being used around the world to facilitate policy discussions and shape intervention strategies. It is also being modified for local purposes by the in-country teams and being used as a comparator with existing in-country models.

Please see the CoMo Consortium PDF for further details.

- Thank you Rima Shretta for this text and images


What is mathematical modeling and how can it help control the COVID-19 pandemic?
Video produced by
WHO Eastern Mediterranean Region

 

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.